Pfizer Essential Health Is Staying Put And Has A Focused Strategy For Growth
Executive Summary
With a new name and focused strategy, Pfizer’s Essential Health business has evolved since the acquisition of Hospira in 2015. Group President John Young outlined the company’s plans to transition a unit that was established to manage patent expirations to become a growth center.
You may also be interested in...
Pfizer Plays Up Its In-house Potential, Avoids M&A Talk
Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.
Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Pfizer hopes positive top-line Phase III trial data on its Herceptin (trastuzumab) biosimilar can help it tap the lucrative market in HER2-overexpressing cancers, but analysts say that therapeutic space looks increasingly crowded with no clear favorite yet in sight.
Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Pfizer hopes positive top-line Phase III trial data on its Herceptin (trastuzumab) biosimilar can help it tap the lucrative market in HER2-overexpressing cancers, but analysts say that therapeutic space looks increasingly crowded with no clear favorite yet in sight.